PMID- 35059792
OWN - NLM
STAT- MEDLINE
DCOM- 20220916
LR  - 20220916
IS  - 1434-4726 (Electronic)
IS  - 0937-4477 (Linking)
VI  - 279
IP  - 10
DP  - 2022 Oct
TI  - Real life safety of systemic steroids for sudden sensorineural hearing loss: a 
      chart review.
PG  - 4787-4792
LID - 10.1007/s00405-022-07264-3 [doi]
AB  - OBJECTIVES: To report adverse events (AEs) associated with systemic steroid 
      treatment in idiopathic sudden sensorineural hearing loss (ISSNHL). MATERIAL AND 
      METHODS: A retrospective chart review of consecutive patients newly diagnosed 
      with ISSNHL necessitating systemic steroidal treatment was conducted from 1/2017 
      to 2/2021. Blood pressure (BP) was monitored three times daily and morning 
      fasting glucose was monitored once daily during treatment. An AE was defined as a 
      fasting blood glucose level > 160 mg/dl, systolic BP > 80 mmHg, and diastolic 
      BP > 100 mmHg. RESULTS: In total, 143 patients were enrolled [69 (48%) males and 
      74 (52%) females] of whom 29 (20%) had diabetes mellitus (DM) and 46 (32%) had 
      hypertension (HTN). The cohort's median age (interquartile range) was 58 (37-69) 
      years. Fifty-three patients (37%) did not complete the oral steroidal treatment 
      due to any AE (glycemic or hypertensive). Background DM highly correlated with 
      increased risk of a glycemic event (0.59 vs. 0.13 for diabetic and non-diabetic 
      patients, respectively, P < 0.001). HTN correlated significantly with increased 
      risk of an overall AE (0.54 vs. 0.29 for hypertensive and non-hypertensive 
      patients, respectively, P = 0.001). Neither pre-treatment BP nor glucose level 
      predicted the risk of an AE (P = 0.310 and 0.521, respectively). CONCLUSIONS: AEs 
      due to systemic steroidal treatment are common among ISSNHL patients. Demographic 
      and baseline values cannot predict the risk of AEs which can occur throughout the 
      entire duration of treatment. Patients with DM and HTN are at the greatest risk 
      of AEs. Tight blood glucose and BP monitoring are recommended during treatment.
CI  - (c) 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Halevy, Nir
AU  - Halevy N
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Elias, Bshara
AU  - Elias B
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Shilo, Shahaf
AU  - Shilo S
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Muhanna, Nidal
AU  - Muhanna N
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Handzel, Ophir
AU  - Handzel O
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Oron, Yahav
AU  - Oron Y
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Abu Eta, Rani
AU  - Abu Eta R
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Ungar, Omer J
AU  - Ungar OJ
AUID- ORCID: 0000-0002-5904-1291
AD  - Department of Otolaryngology Head and Neck Surgery and Maxillofacial Surgery, Tel 
      Aviv Sourasky Medical Center, 6 Weizmann Street, 6423906, Tel Aviv, Israel. 
      ungaromer@gmail.com.
AD  - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 
      ungaromer@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20220120
PL  - Germany
TA  - Eur Arch Otorhinolaryngol
JT  - European archives of oto-rhino-laryngology : official journal of the European 
      Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the 
      German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
JID - 9002937
RN  - 0 (Blood Glucose)
RN  - 0 (Steroids)
SB  - IM
MH  - Blood Glucose
MH  - Female
MH  - *Hearing Loss, Sensorineural/diagnosis
MH  - *Hearing Loss, Sudden/diagnosis
MH  - Humans
MH  - *Hypertension/complications/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Retrospective Studies
MH  - Steroids/adverse effects
OTO - NOTNLM
OT  - Idiopathic sudden sensorineural hearing loss
OT  - Systemic steroids
EDAT- 2022/01/22 06:00
MHDA- 2022/09/17 06:00
CRDT- 2022/01/21 06:30
PHST- 2021/09/29 00:00 [received]
PHST- 2022/01/10 00:00 [accepted]
PHST- 2022/01/22 06:00 [pubmed]
PHST- 2022/09/17 06:00 [medline]
PHST- 2022/01/21 06:30 [entrez]
AID - 10.1007/s00405-022-07264-3 [pii]
AID - 10.1007/s00405-022-07264-3 [doi]
PST - ppublish
SO  - Eur Arch Otorhinolaryngol. 2022 Oct;279(10):4787-4792. doi: 
      10.1007/s00405-022-07264-3. Epub 2022 Jan 20.